ATE435302T1 - Verfahren zur vorhersage des behandlungserfolgs mit rivastigmine basierend auf einer bestimmung des apoe genotyps eines demenzkranken - Google Patents

Verfahren zur vorhersage des behandlungserfolgs mit rivastigmine basierend auf einer bestimmung des apoe genotyps eines demenzkranken

Info

Publication number
ATE435302T1
ATE435302T1 AT03747881T AT03747881T ATE435302T1 AT E435302 T1 ATE435302 T1 AT E435302T1 AT 03747881 T AT03747881 T AT 03747881T AT 03747881 T AT03747881 T AT 03747881T AT E435302 T1 ATE435302 T1 AT E435302T1
Authority
AT
Austria
Prior art keywords
rivastigmine
determination
treatment success
apoe genotype
predicting treatment
Prior art date
Application number
AT03747881T
Other languages
English (en)
Inventor
Roger Lane
Mihael Polymeropoulos
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE435302T1 publication Critical patent/ATE435302T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
AT03747881T 2002-08-07 2003-08-06 Verfahren zur vorhersage des behandlungserfolgs mit rivastigmine basierend auf einer bestimmung des apoe genotyps eines demenzkranken ATE435302T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40169402P 2002-08-07 2002-08-07
PCT/EP2003/008719 WO2004015140A1 (en) 2002-08-07 2003-08-06 Methods for the treatment of dementia based on apo e genotype

Publications (1)

Publication Number Publication Date
ATE435302T1 true ATE435302T1 (de) 2009-07-15

Family

ID=31715721

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03747881T ATE435302T1 (de) 2002-08-07 2003-08-06 Verfahren zur vorhersage des behandlungserfolgs mit rivastigmine basierend auf einer bestimmung des apoe genotyps eines demenzkranken

Country Status (14)

Country Link
US (3) US20060160079A1 (de)
EP (1) EP1529116B1 (de)
JP (1) JP2005534710A (de)
CN (1) CN1681941A (de)
AT (1) ATE435302T1 (de)
AU (1) AU2003266967B2 (de)
BR (1) BR0313588A (de)
CA (1) CA2494585A1 (de)
DE (1) DE60328198D1 (de)
DK (1) DK1529116T3 (de)
ES (1) ES2327914T3 (de)
IL (1) IL166466A0 (de)
PT (1) PT1529116E (de)
WO (1) WO2004015140A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
CA2571856A1 (en) * 2004-07-20 2006-02-09 Wyeth Methods of identifying patients at risk of developing encephalitis following immunotherapy for alzheimer's disease
CA2596523A1 (en) * 2005-01-31 2006-08-10 Perlegen Sciences, Inc. Genetic basis of alzheimer's disease and diagnosis and treatment thereof
US7740593B2 (en) 2005-12-09 2010-06-22 Senorx, Inc Guide block for biopsy or surgical devices
KR101335021B1 (ko) 2007-07-31 2013-12-12 액세라인크 게놈 테스트의 용도 및 인지 기능 저하 치료용 케톤성 화합물
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
KR101734152B1 (ko) 2008-07-03 2017-05-11 액세라인크 신경계 장애의 치료를 위한 아세토아세테이트의 모노글리세리드 및 유도체
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
WO2015020523A1 (en) 2013-08-07 2015-02-12 Stichting Vu-Vumc Biomarkers for early diagnosis of alzheimer's disease
CA3057289A1 (en) 2017-03-21 2018-09-27 The Jackson Laboratory A genetically modified mouse expressing human apoe4 and mouse trem2 p.r47h and methods of use thereof
CN111032038A (zh) * 2017-05-24 2020-04-17 H.隆德贝克有限公司 用于治疗阿尔茨海默氏病的药物组合
US20210195879A1 (en) * 2018-06-21 2021-07-01 The Jackson Laboratory Genetically modified mouse models of alzheimer's disease
WO2020176846A2 (en) * 2019-02-28 2020-09-03 The Rockefeller University Apoe genotyping in cancer prognostics and treatment
CN114728875A (zh) 2019-12-13 2022-07-08 因思博纳公司 金属盐及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE262592T1 (de) * 1992-10-13 2004-04-15 Univ Duke Verfahren zum nachweis der alzheimer krankheit
CA2111503A1 (en) * 1993-12-15 1995-06-16 Mcgill University Apolipoprotein e polymorphism and alzheimer's disease
FR2765591B1 (fr) * 1997-07-01 2002-08-09 Pasteur Institut Procede de diagnostic de la maladie d'alzheimer
CO4980891A1 (es) * 1997-11-14 2000-11-27 Sanofi Sa Asociacion de principios activos para el tratamiento de la demencia senil de tipo azheimer
JP2000069963A (ja) * 1998-08-31 2000-03-07 Igaku Seibutsugaku Kenkyusho:Kk アポリポプロテインｅ４特異モノクローナル抗体
ES2237163T3 (es) * 1998-10-01 2005-07-16 Novartis Ag Nuevas formulaciones orales de revastigmina de liberacion controlada.
DE60116313T2 (de) * 2000-06-30 2006-08-31 Elan Pharmaceuticals, Inc., San Francisco Verbindungen zur behandlung der alzheimerischen krankheit

Also Published As

Publication number Publication date
US20060160079A1 (en) 2006-07-20
DE60328198D1 (de) 2009-08-13
EP1529116A1 (de) 2005-05-11
IL166466A0 (en) 2006-01-15
CN1681941A (zh) 2005-10-12
WO2004015140A1 (en) 2004-02-19
US20100240744A1 (en) 2010-09-23
AU2003266967A1 (en) 2004-02-25
US20080214662A1 (en) 2008-09-04
ES2327914T3 (es) 2009-11-05
DK1529116T3 (da) 2009-11-09
JP2005534710A (ja) 2005-11-17
EP1529116B1 (de) 2009-07-01
CA2494585A1 (en) 2004-02-19
AU2003266967B2 (en) 2006-11-16
PT1529116E (pt) 2009-09-10
BR0313588A (pt) 2005-07-12

Similar Documents

Publication Publication Date Title
IL166466A0 (en) Methods for the treatment of dementia based on apoe genotype
ATE526041T1 (de) Verfahren zur hemmung okularer vorgänge
ATE488251T1 (de) Verfahren zur diagnose und behandlung von schwangerschaftsskomplikationen
ATE526421T1 (de) Verfahren und reagenzien zur behandlung und diagnose von altersbedingter makuladegeneration
ATE503563T1 (de) Blockverhältnisverbesserendes mittel für permeable membran, verfahren zur blockverhältnisverbesserung, permebale membran und wasserbehandlungsverfahren
MX2007016136A (es) Metodo para diagnosticar la enfermedad de alzheimer.
DE602005023363D1 (de) Vorrichtung und Verfahren zur Authentifizierung von Blutgefässen
TW200731984A (en) C3-convertase inhibitors for the prevention and treatment of age-related macular degeneration in patients with at risk variants of complement factor H
ATE426043T1 (de) Verfahren zur identifizierung des brustkrebsrisikos
WO2006028999A3 (en) Assessment of ctla-4 polymorphisms in ctla-4 blockade therapy
WO2007006862A3 (en) Method and kit for detecting a risk of coronary heart disease
ATE474066T1 (de) Verfahren zum nachweis von pathogenen mittels molecular beacons
WO2004043232A3 (en) Methods for identifying risk of melanoma and treatments thereof
WO2005014846A3 (en) Methods for identifying risk of breast cancer and treatments thereof
EP1899726A4 (de) Verfahren zur diagnose und behandlung auf nr2-peptiden beruhender zerebrovaskulärer ereignisse
DE602005020113D1 (de) Verfahren zur behandlung von akuten rhinosinusitis
WO2006053955A3 (en) Method and kit for detecting a risk of essential arterial hypertension
ATE543429T1 (de) Verfahren zur bestimmung des sympathikus-tonus und messsystem dafür
WO2006022619A3 (en) Methods for identifying risk of type ii diabetes and treatments thereof
DE602005016697D1 (de) Molekulardiagnoseverfahren und behandlung von demenz mit lewy-körperchen
WO2006053252A3 (en) Methods of treating hematological malignancies with nucleoside analog drugs
DE602006007734D1 (de) Verfahren und system zur echtzeitanalyse von biosensordaten
ATE432996T1 (de) Verfahren zur bestimmung des bodenzustands
WO2005118834A3 (en) Methods for identifying risk of breast cancer and treatment thereof
WO2007013359A3 (en) Cancer related gene rasgef1a

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1529116

Country of ref document: EP

REN Ceased due to non-payment of the annual fee